SCHEMBL26964751

SCHEMBL26964751

Cn1nc(COCC(F)(F)F)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
GRN P28799 2/20 0.46
SORT1 Q99523 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 2/20 0.40
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CHRM3 P20309 1/20 0.34
NPC1 O15118 1/20 0.34
JMJD6 Q6NYC1 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
CCNE1 P24864 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25346661 0.87 GRN (0.47) ALDH1A1GRNSORT1KDM4EPKM
Lithium Ion SCHEMBL26964599 0.86 ALDH1A1 (0.39) ALDH1A1GRNSORT1KDM4EPKM
SCHEMBL29148534 0.85 GRN (0.46) ALDH1A1GRNSORT1KDM4EPKM
Lithium SCHEMBL30645663 0.85 GRN (0.46) ALDH1A1GRNSORT1KDM4EPKM
SCHEMBL26964701 0.83 RAB9A (0.44) ALDH1A1KDM4ECA12CA1CA2
SCHEMBL28701604 0.81 GRN (0.51) ALDH1A1GRNSORT1KDM4EPKM
SCHEMBL22286724 0.80 KDM4E (0.49) ALDH1A1GRNSORT1KDM4ECA12
SCHEMBL15932104 0.79 SRD5A2 (0.47) ALDH1A1GRNSORT1KDM4EPKM
SCHEMBL26964715 0.78 KDM4E (0.44) ALDH1A1GRNSORT1KDM4EPKM
SCHEMBL13365066 0.78 PKM (0.54) ALDH1A1GRNSORT1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190855-A1 CDK INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2024-06-13 US disclosed
EP-4291176-A1 CDK INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2023-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190855-A1 CDK INHIBITORS AND METHODS OF USE THEREOF CDK3, CDK8, CDK6 ALDH1A1 3717/4885GRN 3035/4885SORT1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.